Sai Parenteral's share price: Stock lists at 2% premium; here's how much investors made per lot

The stock listed at ₹400 per share on the National Stock Exchange (NSE), reflecting a premium of 2.04% compared to the issue price of ₹392 per share.

On the BSE, the scrip started trading at ₹405, up 3.32% from the issue price.

Sai Parenteral's share price: Here's how much investors lost per lot

The ₹408.79 crore IPO was a mix of a fresh issue of shares aggregating to ₹285 crore and an offer-for-sale (OFS) of ₹123.79 crore.

Under the OFS, Vikasa India EIF I Fund, Tilokchand Punamchand Ostwal, Devendra Chawla, Bhanwar Lal Chandak, Ashish Maheshwari, Vijay Gondi, Padma Guntupalli, Nilesh Pravinchandra Doshi, Sreelekha Ganta and Bhautik Mukund Shah offloaded their stake.

The funds generated will be utilised to support the company's expansion, debt repayment, working capital needs, establish a new R&D centre, invest in a wholly-owned unit and general corporate purposes.

The initial public offering, with a price band of ₹201 to ₹212 per share, was subscribed 1.05 times, with bids for 78,80,972 shares as against 75,22,486 shares on offer, according to the NSE data.

Sai Parenteral's is a diversified pharmaceutical formulations company with capabilities in R&D (research and development) and manufacturing. It is involved in the business of CDMO (contract development and manufacturing organisation) products and branded generic formulations for the domestic and international markets.

The product portfolio spans multiple therapeutic areas including anti-diabetic, cardiovascular, respiratory health, antibiotics, gastroenterology, vitamins, neuropsychiatry, minerals and supplements, analgesics, and dermatology.